Immediate clinical effectiveness of bepotastine besilate for patients with urticaria

Futoshi Kohda, Masutaka Furue, Shinichi Imafuku

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

A questionnaire survey concerning the immediate efficacy of bepotastine besilate (Talion®) was administered to 25 patients with urticaria. All 20 of the 20 patients (100%) who answered the question "When did you feel the effect of inhibition of itching?" reported noticing such an effect within 90 minutes after taking the medicine. Moreover, 92% expressed the opinion that they were conscious of the medication's effectiveness. As for duration of the effect, of 19 patients, 16% reported 4 hours, 32% reported 8 hours, and 47% reported 12 hours. Even though 33% of the patients reported drowsiness as a side effect, 84% wanted to continue using this medicine, proving its high efficacy.

元の言語英語
ページ(範囲)544-547
ページ数4
ジャーナルNishinihon Journal of Dermatology
68
発行部数5
DOI
出版物ステータス出版済み - 10 31 2006

Fingerprint

Urticaria
Medicine
Sleep Stages
Pruritus
bepotastine besilate

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

Immediate clinical effectiveness of bepotastine besilate for patients with urticaria. / Kohda, Futoshi; Furue, Masutaka; Imafuku, Shinichi.

:: Nishinihon Journal of Dermatology, 巻 68, 番号 5, 31.10.2006, p. 544-547.

研究成果: ジャーナルへの寄稿記事

@article{a2a6c741c98d4a9c98783d50c3ba80fc,
title = "Immediate clinical effectiveness of bepotastine besilate for patients with urticaria",
abstract = "A questionnaire survey concerning the immediate efficacy of bepotastine besilate (Talion{\circledR}) was administered to 25 patients with urticaria. All 20 of the 20 patients (100{\%}) who answered the question {"}When did you feel the effect of inhibition of itching?{"} reported noticing such an effect within 90 minutes after taking the medicine. Moreover, 92{\%} expressed the opinion that they were conscious of the medication's effectiveness. As for duration of the effect, of 19 patients, 16{\%} reported 4 hours, 32{\%} reported 8 hours, and 47{\%} reported 12 hours. Even though 33{\%} of the patients reported drowsiness as a side effect, 84{\%} wanted to continue using this medicine, proving its high efficacy.",
author = "Futoshi Kohda and Masutaka Furue and Shinichi Imafuku",
year = "2006",
month = "10",
day = "31",
doi = "10.2336/nishinihonhifu.68.544",
language = "English",
volume = "68",
pages = "544--547",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Immediate clinical effectiveness of bepotastine besilate for patients with urticaria

AU - Kohda, Futoshi

AU - Furue, Masutaka

AU - Imafuku, Shinichi

PY - 2006/10/31

Y1 - 2006/10/31

N2 - A questionnaire survey concerning the immediate efficacy of bepotastine besilate (Talion®) was administered to 25 patients with urticaria. All 20 of the 20 patients (100%) who answered the question "When did you feel the effect of inhibition of itching?" reported noticing such an effect within 90 minutes after taking the medicine. Moreover, 92% expressed the opinion that they were conscious of the medication's effectiveness. As for duration of the effect, of 19 patients, 16% reported 4 hours, 32% reported 8 hours, and 47% reported 12 hours. Even though 33% of the patients reported drowsiness as a side effect, 84% wanted to continue using this medicine, proving its high efficacy.

AB - A questionnaire survey concerning the immediate efficacy of bepotastine besilate (Talion®) was administered to 25 patients with urticaria. All 20 of the 20 patients (100%) who answered the question "When did you feel the effect of inhibition of itching?" reported noticing such an effect within 90 minutes after taking the medicine. Moreover, 92% expressed the opinion that they were conscious of the medication's effectiveness. As for duration of the effect, of 19 patients, 16% reported 4 hours, 32% reported 8 hours, and 47% reported 12 hours. Even though 33% of the patients reported drowsiness as a side effect, 84% wanted to continue using this medicine, proving its high efficacy.

UR - http://www.scopus.com/inward/record.url?scp=33750282215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750282215&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.68.544

DO - 10.2336/nishinihonhifu.68.544

M3 - Article

AN - SCOPUS:33750282215

VL - 68

SP - 544

EP - 547

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 5

ER -